MTOR and neoplasm: - Expression in pDCs suppresses T-cell responses in TDLN (77) and activates Tregs in tumor microenvironment and TDLN (60, 61, 78) - Expression in DCs and MDSCs implicated in anti-PD-1 resistance (79) - Expression in MDSCs impairs AMPK and mTOR function (80)